28.46

1.86% 0.52

After Hours: 28.46

Harmony Biosciences Holdings Inc (HRMY)

Overview News Price History Option Chain Financials Why HRMY Down? Discussions Forecast

Harmony Biosciences Holdings Inc stock is traded at $28.46, with a volume of 456.31K. It is up +1.86% in the last 24 hours and down -17.07% over the past month. Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Previous Close:

$27.94

Open:

$27.95

24h Volume:

456.31K

Relative Volume:

0.69

Market Cap:

$1.69B

Revenue:

$681.88M

Net Income/Loss:

$122.63M

P/E Ratio:

13.49

EPS:

2.11

Net Cash Flow:

$220.18M

1W Performance:

-1.83%

1M Performance:

-17.07%

6M Performance:

-18.62%

1Y Performance:

-2.50%

1-Day Range:

$27.95

$28.54

1-Week Range:

$27.56

$29.67

52-Week Range:

$26.47

$41.61

Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile

Name

Harmony Biosciences Holdings Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

(484) 539-9800

Address

630 W GERMANTOWN PIKE, PLYMOUTH MEETING

Employee

268

Twitter

Next Earnings Date

2024-10-29

Latest SEC Filings

HRMY's Discussions on Twitter

Compare HRMY with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HRMY Harmony Biosciences Holdings Inc	28.46	1.69B	681.88M	122.63M	220.18M	2.11
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-11-25	Initiated	Deutsche Bank	Buy
Dec-17-24	Initiated	H.C. Wainwright	Buy
Oct-10-24	Resumed	Raymond James	Outperform
Sep-10-24	Initiated	UBS	Buy
Jun-21-24	Initiated	Citigroup	Buy
Jan-02-24	Downgrade	BofA Securities	Neutral → Underperform
Sep-25-23	Downgrade	Goldman	Neutral → Sell
Sep-07-23	Initiated	Berenberg	Buy
Apr-20-23	Initiated	BofA Securities	Neutral
Oct-14-22	Upgrade	Janney	Neutral → Buy
Oct-14-22	Upgrade	Jefferies	Hold → Buy
Aug-03-22	Downgrade	Jefferies	Buy → Hold
Jul-13-22	Downgrade	Goldman	Buy → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Apr-14-22	Initiated	Cantor Fitzgerald	Overweight
Dec-01-21	Initiated	Oppenheimer	Outperform
Nov-04-21	Initiated	Raymond James	Outperform
Sep-23-21	Initiated	Needham	Buy
Mar-29-21	Upgrade	Goldman	Neutral → Buy
Sep-14-20	Initiated	Goldman	Neutral
Sep-14-20	Initiated	Jefferies	Buy
Sep-14-20	Initiated	Piper Sandler	Overweight

View All

Harmony Biosciences Holdings Inc Stock (HRMY) Latest News

Apr 18, 2025

Harmony Biosciences Presents Positive Data on ZYN002 for Fragile X Syndrome - MSN

Apr 18, 2025

Apr 17, 2025

Geode Capital Management LLC Has $31.08 Million Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World

Apr 17, 2025

Apr 16, 2025

(HRMY) Technical Data - news.stocktradersdaily.com

Apr 16, 2025

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Bought by JPMorgan Chase & Co. - Defense World

Apr 16, 2025

Franklin Resources Inc. Has $1.10 Million Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World

Apr 16, 2025

Apr 12, 2025

Harmony Biosciences Appoints Ron Philip to Board of Directors - MSN

Apr 12, 2025

Apr 10, 2025

Harmony Biosciences (NASDAQ:HRMY) Earns “Buy” Rating from HC Wainwright - Defense World

Apr 10, 2025

Apr 08, 2025

Breaking Down Harmony Biosciences Hldgs: 13 Analysts Share Their Views - Benzinga

Apr 08, 2025

Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome - BioSpace

Apr 08, 2025

Oppenheimer maintains Harmony Biosciences Outperform rating By Investing.com - Investing.com South Africa

Apr 08, 2025

Developmental and Epileptic Encephalopathies Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.

Apr 08, 2025

Oppenheimer on Harmony Biosciences (HRMY): 'we remain pleased with WAKIX's 4Q24 performance' - StreetInsider

Apr 08, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Connect - markets.businessinsider.com

Apr 08, 2025

Harmony Biosciences reports progress in Fragile X syndrome gel treatment - Investing.com

Apr 08, 2025

Apr 07, 2025

HRMY stock touches 52-week low at $27.87 amid market shifts By Investing.com - Investing.com South Africa

Apr 07, 2025

HRMY stock touches 52-week low at $27.87 amid market shifts - Investing.com India

Apr 07, 2025

Corebridge Financial Inc. Raises Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World

Apr 07, 2025

Vanguard Group Inc. Has $162.88 Million Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - The AM Reporter

Apr 07, 2025

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock Holdings Increased by Vanguard Group Inc. - Defense World

Apr 07, 2025

Arrowstreet Capital Limited Partnership Has $10.21 Million Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - The AM Reporter

Apr 07, 2025

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Rating of “Buy” by Analysts - The AM Reporter

Apr 07, 2025

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Apr 07, 2025

Apr 06, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Apr 06, 2025

Apr 04, 2025